Publikationen, an denen er mitarbeitet Jose Pablo Miramontes Gonzalez (9)

2022

  1. Immunohistochemical Assessment of the P53 Protein as a Predictor of Non-Small Cell Lung Cancer Response to Immunotherapy

    Frontiers in bioscience (Landmark edition), Vol. 27, Núm. 3, pp. 88

  2. Influence of DNA Mismatch Repair (MMR) System in Survival and Response to Immune Checkpoint Inhibitors (ICIs) in Non-Small Cell Lung Cancer (NSCLC): Retrospective Analysis

    Biomedicines, Vol. 10, Núm. 2

2021

  1. Dopamine receptors and the kidney: An overview of health-and pharmacological-targeted implications

    Biomolecules, Vol. 11, Núm. 2, pp. 1-16

  2. Immune System Disorders, Cancer and Viral Infections: A New Treatment Opportunity for the Immune Checkpoint Inhibitors

    Life, Vol. 11, Núm. 12

  3. Resistance to immune checkpoint inhibitors secondary to myeloid-derived suppressor cells: A new therapeutic targeting of haematological malignancies

    Journal of Clinical Medicine, Vol. 10, Núm. 9

  4. The influence of diet and probiotics on the response of solid tumours to immunotherapy: Present and future perspectives

    Applied Sciences (Switzerland), Vol. 11, Núm. 18

2020

  1. Author Correction: A new common functional coding variant at the DDC gene change renal enzyme activity and modify renal dopamine function (Scientific Reports, (2019), 9, 1, (5055), 10.1038/s41598-019-41504-7)

    Scientific Reports

  2. VAV3 rs7528153 and VAV3-AS1 rs1185222 polymorphisms are associated with an increased risk of developing hypertension

    European Journal of Internal Medicine, Vol. 80, pp. 60-65

2019

  1. A new common functional coding variant at the DDC gene change renal enzyme activity and modify renal dopamine function

    Scientific Reports, Vol. 9, Núm. 1